Beyond The Numbers: 4 Analysts Discuss Puma Biotechnology Stock

Ratings for Puma Biotechnology (NASDAQ:PBYI) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 4 0 0 0 0
Last 30D 1 0 0 0 0
1M Ago 2 0 0 0 0
2M Ago 1 0 0 0 0
3M Ago 0 0 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $7.0, a high estimate of $7.00, and a low estimate of $7.00. This current average has not changed from the previous average price target.

Interpreting Analyst Ratings: A Closer Look

The standing of Puma Biotechnology among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Edward White HC Wainwright & Co. Maintains Buy $7.00 $7.00
Edward White HC Wainwright & Co. Maintains Buy $7.00 $7.00
Edward White HC Wainwright & Co. Maintains Buy $7.00 $7.00
Edward White HC Wainwright & Co. Maintains Buy $7.00 -

Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Puma Biotechnology. This offers insight into analysts' perspectives on the current state of the company. Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Puma Biotechnology compared to the broader market. Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Puma Biotechnology's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

For valuable insights into Puma Biotechnology's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Puma Biotechnology analyst ratings.

If you are interested in following small-capstock newsand performance you can start by tracking it here.

Unveiling the Story Behind Puma Biotechnology

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Puma Biotechnology's Financial Performance

Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.

Negative Revenue Trend: Examining Puma Biotechnology's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -17.07% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -11.0%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Puma Biotechnology's ROE excels beyond industry benchmarks, reaching -9.22%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Puma Biotechnology's ROA excels beyond industry benchmarks, reaching -2.17%. This signifies efficient management of assets and strong financial health.

Debt Management: Puma Biotechnology's debt-to-equity ratio stands notably higher than the industry average, reaching 2.17. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

How Are Analyst Ratings Determined?

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Latest Ratings for PBYI

Sep 2021CitigroupUpgradesNeutralBuy
Aug 2021RBC CapitalMaintainsSector Perform
Aug 2021Goldman SachsMaintainsSell

View More Analyst Ratings for PBYI

View the Latest Analyst Ratings

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.